首页> 外文期刊>Rambam Maimonides Medical Journal >Immediate and Long-Term Therapy of Patients with Acute Coronary Syndromes with Thienopyridines. Current Status According to the Latest European Society of Cardiology (ESC) Guidelines
【24h】

Immediate and Long-Term Therapy of Patients with Acute Coronary Syndromes with Thienopyridines. Current Status According to the Latest European Society of Cardiology (ESC) Guidelines

机译:噻吩并吡啶类治疗急性冠脉综合征的患者的近期和长期治疗。根据最新的欧洲心脏病学会(ESC)指南的现状

获取原文
           

摘要

For patients with acute coronary syndrome (ACS), the first priority is to alert emergency services. In addition to an ECG (ideally taken during the first medical contact at the patient’s home), the key of life saving is the immediate antithrombotic therapy with acetylsalicylic acid (ASA) and (unless contraindicated) an injection of unfractionated heparin or bivalirudin as an alternative anticoagulant. Dual anti-platelet therapy (ASA combined with other antiplatelet drugs, like thienopyridines) should be started as soon as possible in the ambulance or at the latest in the hospital. For clopidogrel, a loading dose of 600 mg is the standard. To avoid the risk of an unknown low or missing clopidogrel response, prasugrel is recommended instead, with administration of a loading dose of 60 mg, if no contraindication (s/p stroke or TIA) exists. When PCI is planned, the ambulance must head directly to the nearest hospital with continuous (24/7) PCI service within 90 (to 120) minutes. The maintenance dose for clopidogrel is 75 mg/d; a daily double-dose has not proven to be superior, even in “low responders”. For prasugrel, the maintenance dose is usually 10 mg/d. To avoid bleeding complications in patients ≥ 75 y and/or < 60 kg, a prasugrel maintenance dose of 5 mg/d is recommended. The ESC guidelines recommend DAPT for 1 year after ACS in all patients – independent of the type of ACS and independent of whether any or which coronary stent has been implanted. With DAPT, the patient – and not the stent – is treated.Keywords: Acute coronary syndrome, myocardial infarction, clopidogrel, prasugrel, percutaneous coronary intervention, stentBACKGROUNDDespite the extensive scientific knowledge of cardiovascular risk factors and despite educating the general public, cardiovascular diseases continue to be the leading cause of death. Patients with acute coronary syndromes (ACS) are at particular risk. The immediate measures initiated in these patients often determine if the outcome is life or death. The objective of this overview is the evaluation of the current guidelines to effect practical therapy tips for primary and secondary health care providers, with special focus on the antiplatelet treatment with thienopyridines.DEFINITION OF ACUTE CORONARY SYNDROMEDepending on the symptoms and objective findings, ACS comprises three distinct syndromes (Table 1): acute myocardial infarction with persistent ST-segment elevation (STEMI), acute myocardial infarction without ST-segment elevation (NSTEMI), and unstable angina pectoris (UAP). NSTEMI and UAP are often combined to NSTE-ACS. A (presumably) new-onset left bundle branch block (LBBB) is – depending on the symptoms – initially to be regarded as a STEMI. For STEMI, the symptoms and the electrocardiogram (ECG) are sufficient for diagnosis; one does not have to wait for the results of troponin or CK-MB. In an ideal setting with short system delay times, troponin, if determined, would be negative anyway within the first 6 hours after onset of symptoms. For NSTE-ACS, a positive troponin is the first determining factor for NSTEMI (Table 1, Figure 1).Table 1Definition of the three forms of acute coronary syndromes (ACS).Figure 1Suggestion for immediate pre-hospital measures in patients with acute coronary syndromes (ACS). Other dosing or oral administration of acetylsalicylic acid (ASA) – within the frame of the new European Society of Cardiology (ESC) guidelines – may also (more ...)PRE-HOSPITAL EMERGENCY MEASURESThe first priority is to alert emergency services – whatever emergency number applies geographically. In addition to general measures including an ECG (ideally taken during the first medical contact at the patient’s home), the key is the immediate antithrombotic therapy: if possible (independent of any history of pre-existing therapy), acetylsalicylic acid (ASA) 500 mg and (unless contraindicated) an injection of 5,000 IU of unfractionated heparin should be immediately administered. Other dosing o
机译:对于患有急性冠状动脉综合征(ACS)的患者,首要任务是提醒紧急服务。除心电图(理想情况下是在患者家中进行首次就诊时服用)外,挽救生命的关键是立即使用乙酰水杨酸(ASA)进行抗血栓治疗,以及(除非禁用)注射普通肝素或比伐卢定作为替代品抗凝物。应在救护车中尽快或在医院最晚开始双重抗血小板治疗(ASA联合其他抗血小板药物,如噻吩并吡啶类)。对于氯吡格雷,标准剂量为600 mg。为避免出现未知的氯吡格雷反应低或缺失的风险,建议使用普拉格雷,如果不存在禁忌症(s / p中风或TIA),应给予60 mg的负荷剂量。计划进行PCI时,救护车必须在90(至120)分钟内以连续(24/7)PCI服务直接前往最近的医院。氯吡格雷的维持剂量为75 mg / d;即使在“低反应者”中,每日两次剂量也没有被证明是更好的。对于普拉格雷,维持剂量通常为10 mg / d。为避免≥75岁和/或<60 kg的患者发生出血并发症,建议使用普拉格雷维持剂量5 mg / d。 ESC指南建议所有患者在ACS后1年进行DAPT –与ACS的类型无关,并且与是否植入任何冠状动脉支架或冠状动脉支架无关。使用DAPT可以治疗患者而不是支架。关键词:急性冠状动脉综合征,心肌梗塞,氯吡格雷,普拉格雷,经皮冠状动脉介入治疗,支架背景尽管对心血管危险因素有广泛的科学知识,尽管对公众有所教育,但心血管疾病仍在继续成为主要的死亡原因。患有急性冠状动脉综合症(ACS)的患者特别危险。在这些患者中立即采取的措施通常会确定结果是生死。本概述的目的是评估当前指导原则以评估针对初级和二级医疗保健提供者的实用治疗技巧,特别侧重于噻吩并吡啶类抗血小板治疗。急性冠脉综合征的定义根据症状和客观发现,ACS包括三个不同的综合征(表1):急性ST段抬高持续性心肌梗死(STEMI),无ST段抬高持续性急性心肌梗死(NSTEMI)和不稳定型心绞痛(UAP)。 NSTEMI和UAP通常与NSTE-ACS结合使用。根据症状,(可能是)新发的左束支传导阻滞(LBBB)最初被认为是STEMI。对于STEMI,症状和心电图(ECG)足以诊断。不必等待肌钙蛋白或CK-MB的结果。在系统延迟时间短的理想环境中,如果确定肌钙蛋白,则在症状发作后的头6小时内无论如何都是阴性的。对于NSTE-ACS,肌钙蛋白阳性是NSTEMI的第一个决定因素(表1,图1)表1三种急性冠状动脉综合征(ACS)的定义图1建议对急性冠状动脉患者立即采取院前措施综合症(ACS)。在新的欧洲心脏病学会(ESC)指南框架内,乙酰水杨酸(ASA)的其他剂量或口服给药也可能(更多...)院前急诊措施首要的任务是提醒紧急服务–无论发生何种紧急情况数字在地理位置上适用。除了包括心电图在内的一般措施(理想情况下是在患者家中进行首次就诊期间采取的措施)之外,关键在于立即进行抗血栓治疗:如果可能(与既有治疗史无关),乙酰水杨酸(ASA)500除非有禁忌症,否则应立即注射5,000 IU普通肝素。其他剂量o

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号